GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cynosure Inc (NAS:CYNO) » Definitions » Total Inventories

Cynosure (Cynosure) Total Inventories : $76.0 Mil (As of Dec. 2016)


View and export this data going back to 2005. Start your Free Trial

What is Cynosure Total Inventories?

Cynosure's total inventories for the quarter that ended in Dec. 2016 was $76.0 Mil. Cynosure's average total inventories from the quarter that ended in Sep. 2016 to the quarter that ended in Dec. 2016 was $79.9 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Cynosure's Net-Net Working Capital per share for the quarter that ended in Dec. 2016 was $5.86.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Cynosure's Days Inventory for the three months ended in Dec. 2016 was 145.57.

Inventory Turnover measures how fast the company turns over its inventory within a year. Cynosure's Inventory Turnover for the quarter that ended in Dec. 2016 was 0.63.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Cynosure's Inventory-to-Revenue for the quarter that ended in Dec. 2016 was 0.65.


Cynosure Total Inventories Historical Data

The historical data trend for Cynosure's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cynosure Total Inventories Chart

Cynosure Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only 32.91 50.25 59.32 79.77 75.97

Cynosure Quarterly Data
Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 79.77 85.65 83.57 83.93 75.97

Cynosure Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


Cynosure  (NAS:CYNO) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Cynosure's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2016 is

Net-Net Working Capital Per Share (Q: Dec. 2016 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(200.155+0.75 * 42.092+0.5 * 75.972-131.013
-0-0)/23.688
=5.86

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Cynosure's Days Inventory for the three months ended in Dec. 2016 is calculated as:

Days Inventory=Average Total Inventories (Q: Dec. 2016 )/Cost of Goods Sold (Q: Dec. 2016 )*Days in Period
=79.949/50.115*365 / 4
=145.57

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Cynosure's Inventory Turnover for the quarter that ended in Dec. 2016 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Dec. 2016 ) / Average Total Inventories (Q: Dec. 2016 )
=50.115 / 79.949
=0.63

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Cynosure's Inventory to Revenue for the quarter that ended in Dec. 2016 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Dec. 2016 ) / Revenue (Q: Dec. 2016 )
=79.949 / 122.139
=0.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


Cynosure Total Inventories Related Terms

Thank you for viewing the detailed overview of Cynosure's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


Cynosure (Cynosure) Business Description

Traded in Other Exchanges
N/A
Address
Cynosure Inc was incorporated in July 1991. The Company develops and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, liquefy and remove unwanted fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus and ablate sweat glands. It has also developed an aesthetic treatment product for the home use market. The Company sells its products through a direct sales force in North America, France, Spain, the United Kingdom, Germany, Australia, Korea, China, Japan and Mexico and through international distributors in approximately 120 other countries. Its product portfolio is composed of various energy sources including Alexandrite, diode, Nd:YAG, picosecond, pulse dye, and Q-switched lasers and intense pulsed light. It offers single energy source systems as well as workstations that incorporate two or more different types of lasers or pulsed light technologies. It offers multiple technologies and system alternatives at various price points depending mainly on the number and type of energy sources included in the system. Its products are designed to be easily upgradeable to add additional energy sources and handpieces, which provide its customers with technological flexibility as it expand their practices. The Company's latest innovations are SmartLipo system and PicoSure system. The Company's flagship products include Elite, Affirm/SmartSkin, Cynergy, Accolade. The Company sells its aesthetic treatment systems to the traditional physician customer base of dermatologists and plastic surgeons as well as to non-traditional physician customers who are providing aesthetic services using laser and light-based technology. Non-traditional physician customers can include primary care physicians, obstetricians and gynecologists. As of December 31, 2013, the Company owns over 60 United States patents, as well as many United States pending applications and foreign patents and pending applications. It is also joint owners with El.En. of certain patents and pending applications. The Company competes with Cutera, Solta Medical, Syneron Medical, ZELTIQ Aesthetics, Alma Lasers among others. Its products are medical devices subject to extensive and rigorous regulation by the U.S. Food and Drug Administration, or FDA, as well as other regulatory bodies.
Executives
Thomas H Robinson director C/O CYNOSURE, INC., 5 CARISLE ROAD, WESTFORD MA 01886
Marina Hatsopoulos director 39 MANNING ROAD, BILLERICA MA 01821
George J Vojta director 340 PONDFFIELD ROAD, BROXVILLE NY 10708

Cynosure (Cynosure) Headlines

From GuruFocus

Cynosure: A Value Play on Vanity

By guruek Mike Havrilla 01-19-2009

Small Caps: Assessing Management Guidance and Analysts' Estimates

By Robert Abbott Robert Abbott 11-05-2018

Steven Cohen Invests in Cynosure

By David Goodloe David Goodloe 04-26-2016